\
&
Contact us
MSCA Health Culture and society Digital, Industry & Space
The European Commission and/or its agencies organise info days on the 2026 call topics and these are often complemented by brokerage events, organised by National Contact Point (NCP) networks and/or the Enterprise Europe Network (EEN). These events provide opportunities to connect with potential collaboration partners. In addition, several pro... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.